Wan-Qiu Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wan-Qiu Zhu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hebing Zhou
Department of Hematology, The Affiliated Beijing Luhe Hospital of Capital Medical University, Beijing 101149, P.R. China
1 shared publication - Wenming Chen
Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
1 shared publication Xiao-Lei Chen
Department of Hematology, Beijing Lu-He Hospital, Capital Medical University, Beijing, China
1 shared publication- Ying Tian
Chaoyang District, Hematology, Beijing, China Beijing
1 shared publication - Yue Zhang
Department of Geriatrics, Beijing Haidian Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 26 November 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-8
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.
- 26 November 2018
- Published by Wiley in BioMed Research International
- Vol. 2018, 1-8
Open AccessPeripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
The survival of individuals with tumors may be predicted by the peripheral blood lymphocyte-to-monocyte ratio (LMR) upon diagnosis in recent studies. For patients with multiple myeloma (MM) in the era of novel agents, the prognostic significance of LMR remains unclear. In this study, the prognostic impact of LMR is evaluated by 285 patients with MM who are treated with proteasome inhibitor and/or immunomodulatory drug. LMR is a proven predictor of survival using the receiver operating characteristic curve, with 4.2 as the cutoff point. Patients with LMR ≤ 4.2 at diagnosis had poorer overall survival (OS) and progression-free survival (PFS) than those with LMR > 4.2. In addition, multivariate analysis showed that LMR less than 4.2 is an independent predictor for the OS (hazard ratio [HR]: 1.703; 95% confidence interval [CI]: 1.020–2.842;P= 0.042) and PFS (HR: 1.831; 95% CI: 1.098–3.053;P= 0.021). According to the test, the LMR at diagnosis, which functions as a simple index reflecting host systemic immunity, can predict clinical outcomes in patients with MM who are treated with new agents.